Zacks Research Boosts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research increased their Q1 2026 earnings estimates for Globus Medical in a research report issued on Monday, November 4th. Zacks Research analyst R. Department now expects that the medical device company will earn $0.85 per share for the quarter, up from their previous estimate of $0.84. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2026 earnings at $1.03 EPS.

A number of other brokerages have also recently issued reports on GMED. Piper Sandler boosted their target price on Globus Medical from $80.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday. Wells Fargo & Company increased their target price on Globus Medical from $78.00 to $88.00 and gave the company an “overweight” rating in a research note on Wednesday. Roth Mkm reissued a “buy” rating and set a $100.00 price target on shares of Globus Medical in a research report on Wednesday. Royal Bank of Canada increased their price objective on shares of Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, BTIG Research boosted their target price on shares of Globus Medical from $77.00 to $78.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.09.

Globus Medical Trading Down 0.9 %

GMED stock opened at $81.97 on Wednesday. The company has a market cap of $11.10 billion, a PE ratio of 273.23, a price-to-earnings-growth ratio of 2.06 and a beta of 1.17. The stock has a 50-day moving average price of $71.92 and a two-hundred day moving average price of $68.16. Globus Medical has a 12-month low of $43.38 and a 12-month high of $84.87.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.18. The company had revenue of $625.71 million during the quarter, compared to analysts’ expectations of $604.69 million. Globus Medical had a net margin of 1.82% and a return on equity of 8.70%. The business’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.57 EPS.

Institutional Trading of Globus Medical

Several institutional investors have recently added to or reduced their stakes in GMED. Burgundy Asset Management Ltd. boosted its holdings in shares of Globus Medical by 1.4% in the 2nd quarter. Burgundy Asset Management Ltd. now owns 2,514,891 shares of the medical device company’s stock valued at $172,245,000 after buying an additional 35,054 shares during the period. Champlain Investment Partners LLC boosted its stake in Globus Medical by 25.2% in the first quarter. Champlain Investment Partners LLC now owns 2,504,383 shares of the medical device company’s stock valued at $134,335,000 after acquiring an additional 503,745 shares during the period. Magnetar Financial LLC grew its holdings in shares of Globus Medical by 1.7% during the second quarter. Magnetar Financial LLC now owns 1,718,487 shares of the medical device company’s stock valued at $117,699,000 after purchasing an additional 29,200 shares during the last quarter. Geneva Capital Management LLC raised its position in shares of Globus Medical by 1.1% during the 3rd quarter. Geneva Capital Management LLC now owns 1,598,130 shares of the medical device company’s stock worth $114,330,000 after purchasing an additional 18,117 shares during the period. Finally, AXA S.A. lifted its holdings in shares of Globus Medical by 0.5% in the 2nd quarter. AXA S.A. now owns 1,478,242 shares of the medical device company’s stock worth $101,245,000 after purchasing an additional 7,443 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Insider Transactions at Globus Medical

In other news, Director David D. Davidar sold 30,000 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the transaction, the director now owns 536,275 shares of the company’s stock, valued at approximately $40,242,076. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Globus Medical news, Director David D. Davidar sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the sale, the director now owns 536,275 shares in the company, valued at $40,242,076. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Ann D. Rhoads sold 15,000 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $70.36, for a total value of $1,055,400.00. Following the transaction, the director now directly owns 42,884 shares in the company, valued at approximately $3,017,318.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 18.54% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.